<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079846</url>
  </required_header>
  <id_info>
    <org_study_id>MRL 2002-001</org_study_id>
    <nct_id>NCT00079846</nct_id>
  </id_info>
  <brief_title>Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy</brief_title>
  <official_title>Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Laboratories International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Research Laboratories International</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if implitapide, used in conjunction with other&#xD;
      lipid-lowering therapies, is safe and effective when compared to placebo in lowering&#xD;
      low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial&#xD;
      hypercholesterolemia (HoFH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2003</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Implitapide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to participate in this study, patients must meet all of the following inclusion&#xD;
        criteria:&#xD;
&#xD;
          -  be between 8 and 70 years old with a diagnosis of HoFH;&#xD;
&#xD;
          -  be stable on and maintain concomitant therapy with hypolipidemic drugs or treatments;&#xD;
&#xD;
          -  have an appropriate calculated, fasting LDL-C levels and an appropriate triglyceride&#xD;
             (TG) level;&#xD;
&#xD;
          -  be male or nonpregnant, nonlactating female;&#xD;
&#xD;
          -  give informed consent; and&#xD;
&#xD;
          -  meet body weight and height requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In order to participate in this study, patients must not meet any of the following&#xD;
        exclusion criteria:&#xD;
&#xD;
          -  recent myocardial infarction, percutaneous transluminal coronary intervention,&#xD;
             coronary artery bypass graft surgery, or cerebrovascular accident;&#xD;
&#xD;
          -  uncontrolled hypothyroidism or other uncontrolled endocrine disease;&#xD;
&#xD;
          -  known, clinically significant eye abnormalities (e.g., cataracts);&#xD;
&#xD;
          -  appropriate serum creatinine phosphokinase levels;&#xD;
&#xD;
          -  history of liver disease or liver enzyme levels above appropriate levels;&#xD;
&#xD;
          -  alkaline phosphatase above appropriate levels;&#xD;
&#xD;
          -  liver cirrhosis and severe liver steatosis;&#xD;
&#xD;
          -  clinically significant infection, malignancy, or psychosis;&#xD;
&#xD;
          -  use of oral anticoagulants or digoxin, unless the dose has been stable for 4 weeks;&#xD;
&#xD;
          -  participation in any other investigational study, including device or observational&#xD;
             studies, within 30 days;&#xD;
&#xD;
          -  lactating or have a positive serum pregnancy test;&#xD;
&#xD;
          -  history of or current drug or alcohol abuse; or&#xD;
&#xD;
          -  unwillingness to comply with study procedures, including follow-up, as specified by&#xD;
             this protocol, or unwillingness to cooperate fully with the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid Clinic and Community Genomic Center, Complexe Hospitalier de la Sagamie</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid Research Center, CHUL du CHUQ</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipidklinikken - Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>N-0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2005</verification_date>
  <study_first_submitted>March 17, 2004</study_first_submitted>
  <study_first_submitted_qc>March 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2004</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Homozygous Familial Hypercholesterolemia (HoFH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

